S9-Fibronectin, EGF-R, HB-EGF:biomarkers of urothelial damage during intravesical adjuvant therapy?

2013

Intravesical chemotherapy and immunotherapy with BCG represent the standard therapy to prevent recurrence after transurethral resection (TUR) of non-muscle invasive bladder cancer (NMI-BC). Maintenance for at least one year is considered the best regimen. Noteworthy, a relevant number of patients do not complete the planned treatment due to local toxicity of the drug given intravesically1, 2. A major challenge for the urologists is to identify an early urothelial damage biomarker to prevent severe local toxicity requiring treatment interruption and to improve patient's compliance. The preliminary purpose of our research was to verify the possible correlation between urothelial damage induce…

FIBRONECTIN (FN) AND UROTHELIAL DAMAGE SECONDARY TO ADJUVANT INTRAVESICAL THERAPY

2014

Introduction and Objectives: Intravesical chemotherapy has been proven effective in preventing recurrence of low-risk non-muscle invasive bladder cancer (NMIBC). BCG is recognised as the best conservative treatment for intermediate and high risk NMIBC. Maintenance for at least one year is required to ameliorate the efficacy of adjuvant therapy. Discomfort and toxicity often cause interruption of adjuvant therapy, BCG particularly. Almost 50% of the patients undergoing BCG does not complete one year. A biomarker of urothelium damage would be helpful for timely detection of toxicity in order to ameliorate patient’s tolerance and compliance. The aim of the present study was to evaluate the gen…

Fibronectin (FN), epidermal growth factor-receptor (EGF-R) and heparin-binding epidermal growth factor-like (HB-EGF) urinary expressions and topical …

2014

NMI bladder cancer, EGF-R, intravesical therapy. fibronectin

FIBRONECTINA: NUOVO MARKER DI DANNO UROTELIALE NELLA TERAPIA ADIUVANTE INTRAVESCICALE DEI TUMORI VESCICALI NON MUSCOLO INVASIVI

2014

Fibronectin (FN), Epidermal Growth Factor-Receptor (EGF-R) and Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HB-EGF) expressions in rel…

2013

40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

2004

BIOMARKERS OF UROTHELIAL DAMAGE IN PATIENTS TREATED BY ADJUVANT INTRAVESICAL THERAPY

2013

Introduction/Aim: Chemotherapy or BCG given intravesically to prevent recurrence after transurethral resection (TUR) of non-muscle invasive bladder cancer (NMI-BC) cause frequent, sometime severe, local toxicity. As a consequence, many patients do not complete the planned treatment (1). A major challenge for the urologists is to identify an early biomarker of urothelial damage to recognize and prevent local toxicity improving patient’s compliance. The purpose of our research was to investigate the relation between urothelial injury by intravesical treatment and the expression of potential biomarkers in urine and/or in barbotage solution. The urinary HB-EGF expression in interstitial cystiti…